The Lynx Group

ASCO GU 2022 Highlights

Continuous enzalutamide (Xtandi) treatment in combination with docetaxel significantly improved progression-free survival (PFS) compared with placebo plus docetaxel in men with metastatic castration-resistant prostate cancer who had disease progression on enzalutamide alone, according to results from the phase 3b PRESIDE clinical trial.
Read Article

Neoadjuvant enfortumab vedotin (Padcev) showed promising ­antitumor activity in patients with muscle-invasive bladder cancer (MIBC) who were ineligible for cisplatin therapy, according to preliminary findings from cohort H of the phase 1b/2 EV-103 clinical trial.
Read Article

The neoadjuvant combination of avelumab (Bavencio) and axitinib (Inlyta) resulted in a partial response (PR) rate of 30% in ­patients with localized renal-cell carcinoma (RCC) at high risk for relapse after nephrectomy, according to results from the phase 2 NeoAvAx clinical trial.
Read Article

Adjuvant pembrolizumab (Keytruda) continued to provide a disease-free survival (DFS) benefit in patients with renal-cell carcinoma (RCC) at intermediate-high or high risk of recurrence after nephrectomy, according to 30-month follow-up data from the KEYNOTE-564 trial presented at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium.
Read Article

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to receive the free VBCC print publication or weekly e‑Newsletter.

I'd like to receive: